Kidney Week

Abstract: TH-PO619

Efficacy and Safety of Rituximab in Patients with Focal Segmental Glomerulosclerosis (FSGS): A Single-Center Retrospective Cohort

Session Information

• Membranous Nephropathy, FSGS, and Minimal Change Disease
  October 24, 2024 | Location: Exhibit Hall, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Kashkari, Amnah Talal, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh, Saudi Arabia

Amnah Talal Kashkari, MD

• Alagla, Nahlah Abdullah, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh, Saudi Arabia

Nahlah Abdullah Alagla, MD

• Aldalham, Hanin Saad, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh, Saudi Arabia

Hanin Saad Aldalham

• Mohamed, Gamal, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh, Saudi Arabia

Gamal Mohamed, PhD

• Al Hussain, Turki, King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh, Saudi Arabia

Turki Al Hussain, MD

• Alkhawlani, Abeer Abdullah, Alfaisal University College of Medicine, Riyadh, Saudi Arabia

Abeer Abdullah Alkhawlani, MBBS

• Mohamed, Rojina Fathalrahman, Alfaisal University College of Medicine, Riyadh, Saudi Arabia

Rojina Fathalrahman Mohamed, MBBS

• Khan, Bushra Shehroz, Alfaisal University College of Medicine, Riyadh, Saudi Arabia

Bushra Shehroz Khan

• Abodahab, Fawzy M., Alfaisal University College of Medicine, Riyadh, Saudi Arabia

Fawzy M. Abodahab

• Elfar, Ahmed F., King Faisal Specialist Hospital and Research Centre, Riyadh, Riyadh, Saudi Arabia

Ahmed F. Elfar, MD

Background

FSGS is a pattern of glomerular lesion which can be primary or secondary. Current therapy is based on FSGS category, avoiding immunosuppressive therapy in non primary-FSGS. Rituximab may be useful in the management, however clinical evidence in adults is limited. Our study assessed the efficacy of Rituximab in adolescents and adults with FSGS.

Methods

We retrospectively reviewed all biopsy proven FSGS from 2010 to 2021. Patients aged > 14 years who received at least one dose of Rituximab were included. Primary outcome was response rate at 3, 6 and 12 months. It was classified as complete or partial remission according to KDIGO criteria.

Results

A total of 30 patients were included. Baseline characteristics are shown in table 1. Response rate (combined complete and partial) at 3, 6 and 12 months was 67 %,70%, and 69% respectively as in figure 1. At 6 months, 65% of responded patients had B cell depletion. A better response was observed with steroid dependent patients. Median time to first relapse from last Rituximab dose was 11 months with relapse rate of 53%. Regarding safety, mild reactions were reported consistent with the known safety profile of Rituximab.

Conclusion

Our data suggests that Rituximab is effective in FSGS especially those who are steroid dependent. However relapse rate is significant once Rituximab is stopped. To support our result, further studies are needed with larger volume of patients.

Table 1: results are expressed in N (%) for categorical variables and median (interquartile range) for continues variables

Figure 1